Reviewing Jin Medical International (NASDAQ:ZJYL) and biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Insider and Institutional Ownership

21.7% of biote shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for biote and Jin Medical International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	0	2.00
Jin Medical International	1	0	0	0	1.00

biote currently has a consensus price target of $6.00, suggesting a potential upside of 125.56%. Given biote’s stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Jin Medical International.

Profitability

This table compares biote and Jin Medical International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	15.73%	-21.00%	18.26%
Jin Medical International	N/A	N/A	N/A

Valuation & Earnings

This table compares biote and Jin Medical International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$195.65 million	0.62	$3.16 million	$0.79	3.37
Jin Medical International	$23.50 million	1.68	$3.68 million	N/A	N/A

Jin Medical International has lower revenue, but higher earnings than biote.

Volatility and Risk

biote has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Jin Medical International has a beta of 9.28, meaning that its stock price is 828% more volatile than the S&P 500.

Summary

biote beats Jin Medical International on 8 of the 12 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.